share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K:外國發行人報告
美股SEC公告 ·  2024/07/11 06:03

Moomoo AI 已提取核心訊息

XChange TEC received approval from Nasdaq on July 9, 2024, to transfer its listing from The Nasdaq Global Market to The Nasdaq Capital Market. The Nasdaq Hearings Panel granted the company an extension until August 31, 2024, with the condition that it must demonstrate a closing bid price of $1.00 or more per share for at least 10 consecutive trading sessions by August 14, 2024.The company had previously received non-compliance notices from Nasdaq regarding two issues: failure to meet the $50 million requirement in total assets and revenue, and falling below the minimum $1 per share bid price requirement. After submitting a compliance plan on April 5 and appealing Nasdaq's initial denial of continued listing, the company presented its case for transfer to The Nasdaq Capital Market on...Show More
XChange TEC received approval from Nasdaq on July 9, 2024, to transfer its listing from The Nasdaq Global Market to The Nasdaq Capital Market. The Nasdaq Hearings Panel granted the company an extension until August 31, 2024, with the condition that it must demonstrate a closing bid price of $1.00 or more per share for at least 10 consecutive trading sessions by August 14, 2024.The company had previously received non-compliance notices from Nasdaq regarding two issues: failure to meet the $50 million requirement in total assets and revenue, and falling below the minimum $1 per share bid price requirement. After submitting a compliance plan on April 5 and appealing Nasdaq's initial denial of continued listing, the company presented its case for transfer to The Nasdaq Capital Market on June 13.The transfer approval provides XChange TEC with additional time to regain compliance with listing requirements, though there is no assurance the company will meet the conditions set forth in the Panel Decision Letter. The company operates insurance agency and insurance technology businesses in China, including developing SaaS platforms for insurance services.
XChange TEC於2024年7月9日獲得納斯達克的批准,將其上市從納斯達克全球市場轉移至納斯達克資本市場。納斯達克聽證小組給予公司延期至2024年8月31日,條件是必須在2024年8月14日前的至少10個連續交易日內,展示每股1.00美元或更高的收盤買盤價。該公司之前曾收到納斯達克關於兩個問題的不合規通知:未能滿足5000萬的總資產和營業收入要求,以及低於每股1美元的最低買盤價要求。在4月5日提交合規計劃並對納斯達克最初拒絕持續上市的決定提出上訴後,該公司於6月13日提出了轉移至納斯達克資本市場的案例。該轉移批准爲XChange TEC提供了額外的時間,以重新獲得合規上市要求,儘管公司未必會滿足聽證小組決策信中列出的條件。該公司在中國運營保險代理和保險科技業務,包括開發用於保險服務的Saas-雲計算平台。
XChange TEC於2024年7月9日獲得納斯達克的批准,將其上市從納斯達克全球市場轉移至納斯達克資本市場。納斯達克聽證小組給予公司延期至2024年8月31日,條件是必須在2024年8月14日前的至少10個連續交易日內,展示每股1.00美元或更高的收盤買盤價。該公司之前曾收到納斯達克關於兩個問題的不合規通知:未能滿足5000萬的總資產和營業收入要求,以及低於每股1美元的最低買盤價要求。在4月5日提交合規計劃並對納斯達克最初拒絕持續上市的決定提出上訴後,該公司於6月13日提出了轉移至納斯達克資本市場的案例。該轉移批准爲XChange TEC提供了額外的時間,以重新獲得合規上市要求,儘管公司未必會滿足聽證小組決策信中列出的條件。該公司在中國運營保險代理和保險科技業務,包括開發用於保險服務的Saas-雲計算平台。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息